WE have doubts over the preliminary findings of the Cost-Benefit Assessment (CBA) 2.0 on the impact of the Medicines Price Regulation (MPR) policy, which were opened for public consultation recently (Nov 29 and Dec 6).
Although the study summary stated that patient advocacy groups had been approached for “expert views”, none of our societies were invited.
